Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pfizer Inc. is currently conducting a Phase 3 clinical study titled ‘MagnetisMM-32’ to evaluate the effectiveness of the drug elranatamab in treating relapsed or refractory multiple myeloma (MM) in patients who have previously undergone anti-CD38 therapy. The study aims to compare elranatamab with other combination therapies to assess its safety and efficacy.
The intervention being tested is elranatamab, administered as a subcutaneous injection. It is compared against other treatments, including combinations of drugs like elotuzumab, pomalidomide, dexamethasone, bortezomib, and carfilzomib, which are administered in various forms.
This interventional study employs a randomized, parallel assignment model with no masking, focusing primarily on treatment. Participants are divided into two groups to receive either elranatamab or a combination therapy selected by the study doctor.
The study began on February 8, 2024, with an estimated completion date in 2025. The last update was submitted on June 23, 2025, indicating ongoing recruitment and progress.
The outcome of this study could significantly impact Pfizer’s stock performance and investor sentiment, as successful results may enhance their competitive position in the oncology market. Investors should monitor this study closely, considering the competitive landscape of multiple myeloma treatments.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.